News coverage about Dermira (NASDAQ:DERM) has trended positive this week, according to Alpha One Sentiment. Alpha One, a service of Accern, scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dermira earned a coverage optimism score of 0.26 on Alpha One’s scale. Alpha One also gave headlines about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the near future.
Shares of Dermira (NASDAQ DERM) traded down 1.68% during trading on Friday, hitting $28.75. 686,051 shares of the stock were exchanged. Dermira has a 52-week low of $25.63 and a 52-week high of $38.75. The firm has a 50 day moving average of $28.84 and a 200-day moving average of $31.32. The stock’s market cap is $1.19 billion.
A number of equities analysts have recently commented on the stock. BidaskClub raised shares of Dermira from a “sell” rating to a “hold” rating in a report on Thursday. Mizuho decreased their price target on shares of Dermira from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, May 25th. Guggenheim reissued a “positive” rating and issued a $40.00 price target on shares of Dermira in a report on Thursday, March 2nd. Raymond James Financial, Inc. assumed coverage on shares of Dermira in a report on Thursday, March 16th. They issued an “underperform” rating on the stock. Finally, Citigroup Inc. assumed coverage on shares of Dermira in a report on Wednesday, March 15th. They issued an “underperform” rating on the stock. They noted that the move was a valuation call. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. Dermira has an average rating of “Hold” and an average target price of $42.00.
ILLEGAL ACTIVITY NOTICE: “Dermira (DERM) Getting Favorable Media Coverage, Analysis Finds” was first reported by WKRB News and is the sole property of of WKRB News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.wkrb13.com/markets/2230623/dermira-derm-getting-favorable-media-coverage-analysis-finds.html.
In related news, SVP Christopher M. Griffith sold 1,312 shares of the company’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $27.07, for a total transaction of $35,515.84. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Thomas G. Wiggans sold 5,000 shares of the company’s stock in a transaction on Friday, June 2nd. The shares were sold at an average price of $27.52, for a total transaction of $137,600.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,615 shares of company stock worth $586,139. 17.30% of the stock is owned by insiders.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230623/dermira-derm-getting-favorable-media-coverage-analysis-finds.html
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.